Cargando…
Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the im...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963624/ https://www.ncbi.nlm.nih.gov/pubmed/36837875 http://dx.doi.org/10.3390/metabo13020256 |
_version_ | 1784896298065854464 |
---|---|
author | Katsimichas, Themistoklis Theofilis, Panagiotis Tsioufis, Konstantinos Tousoulis, Dimitris |
author_facet | Katsimichas, Themistoklis Theofilis, Panagiotis Tsioufis, Konstantinos Tousoulis, Dimitris |
author_sort | Katsimichas, Themistoklis |
collection | PubMed |
description | The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context. |
format | Online Article Text |
id | pubmed-9963624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99636242023-02-26 Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives Katsimichas, Themistoklis Theofilis, Panagiotis Tsioufis, Konstantinos Tousoulis, Dimitris Metabolites Review The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context. MDPI 2023-02-09 /pmc/articles/PMC9963624/ /pubmed/36837875 http://dx.doi.org/10.3390/metabo13020256 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Katsimichas, Themistoklis Theofilis, Panagiotis Tsioufis, Konstantinos Tousoulis, Dimitris Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title | Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title_full | Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title_fullStr | Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title_full_unstemmed | Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title_short | Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives |
title_sort | gut microbiota and coronary artery disease: current therapeutic perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963624/ https://www.ncbi.nlm.nih.gov/pubmed/36837875 http://dx.doi.org/10.3390/metabo13020256 |
work_keys_str_mv | AT katsimichasthemistoklis gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives AT theofilispanagiotis gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives AT tsioufiskonstantinos gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives AT tousoulisdimitris gutmicrobiotaandcoronaryarterydiseasecurrenttherapeuticperspectives |